Bausch Health Companies Inc. (BHC,BHC.TO) on Wednesday reported a first-quarter net loss of $1.423 billion or $3.82 per share, compared with net loss of $58 million or $0.16 per share for the first quarter of 2025.
Adjusted net income for the quarter was $296 million or $0.78 per share, compared to $220 million or $0.59 per share last year.
Total consolidated reported revenues were $2.52 billion for the first quarter of 2026, compared with $2.26 billion in the first quarter of 2025, an increase of $265 million, or 12%. Revenue increased 7% on an organic basis compared with the first quarter of 2025.
"Our first quarter performance marks twelve consecutive periods of year-over-year growth in revenue, adjusted EBITDA for Bausch Health excluding Bausch + Lomb, reflecting strategic execution and disciplined accountability across our organization. We continue to invest in our pipeline, including the advancement of larsucosterol to treat alcohol-associated hepatitis, while pursuing business development opportunities aligned with our strategic priorities. With this momentum, we reaffirm our full-year 2026 outlook and remain focused on driving sustainable performance and shareholder value," said Thomas J. Appio, Chief Executive Officer, Bausch Health.
Looking forward, the company expects full-year revenues of $10.670 billion - $10.920 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.